Skip to main content
. 2019 Mar 29;10(25):2451–2461. doi: 10.18632/oncotarget.26789

Figure 1.

Figure 1

Waterfall plot showing maximum percentile decline of prostate specific antigen (PSA) to 177Lu-prostate-specific membrane antigen (LuPSMA) radioligand therapy.